Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Ramino-Bio
Ramino-Bio Overview
Ramino Bio is developing an oral drug to treat cardio-metabolic diseases and rare Maple Syrup Urine Disease (MSUD). Ramino Bio’s unique technology addresses the unmet need of several metabolic diseases in the emerging novel elevated BCAA (Branched-chain amino acid) field. With a druggable lead compound, showing efficacy in-vivo, Ramino Bio is heading preclinical stages. First-in-human studies are planned within 18 months with our lead candidate. We are committed to developing effective therapies for the benefit of the patients.